Aims
In the era of personalized therapy liquid biopsy is considered an
important diagnostic tool in the clinical management of cancer patients.
Tissue specimen represents “gold standard” for molecular evaluation of
specific gene targets alterations that lead cancer patients to benefit
of a “tailed therapy” based on molecular features of the tumor. This
innovative source of nucleic acids was introduced in clinical setting
only for NSCLC patients to test Epidermal Grow Factor Receptor (EGFR)
mutations when tissue is not available or to monitor acquired resistance
mutation after a first line of treatment. The study aimed at assessing
the diagnostic potential of liquid biopsy in balanced tertiary screening
modeling.